A detailed history of Virtus ETF Advisers LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 2,058 shares of ALNY stock, worth $489,762. This represents 0.28% of its overall portfolio holdings.

Number of Shares
2,058
Previous 2,058 -0.0%
Holding current value
$489,762
Previous $500,000 13.2%
% of portfolio
0.28%
Previous 0.25%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $2,149 - $3,705
15 Added 0.73%
2,058 $500,000
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $43,073 - $58,270
294 Added 16.81%
2,043 $305,000
Q4 2023

Feb 15, 2024

BUY
$151.41 - $196.57 $32,704 - $42,459
216 Added 14.09%
1,749 $334,000
Q3 2023

Nov 07, 2023

SELL
$170.77 - $211.65 $33,812 - $41,906
-198 Reduced 11.44%
1,533 $271,000
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $76,594 - $87,788
414 Added 31.44%
1,731 $328,000
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $4,383 - $5,652
24 Added 1.86%
1,317 $263,000
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $86,828 - $112,933
-468 Reduced 26.58%
1,293 $307,000
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $3,186 - $5,336
23 Added 1.32%
1,761 $352,000
Q2 2022

Aug 12, 2022

SELL
$120.42 - $169.29 $31,911 - $44,861
-265 Reduced 13.23%
1,738 $253,000
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $118,393 - $155,293
-742 Reduced 27.03%
2,003 $340,000
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $42,607 - $52,140
-251 Reduced 8.38%
2,745 $518,000
Q2 2021

Aug 10, 2021

SELL
$128.63 - $176.89 $221,886 - $305,135
-1,725 Reduced 36.54%
2,996 $508,000
Q1 2021

May 17, 2021

BUY
$126.83 - $175.69 $16,995 - $23,542
134 Added 2.92%
4,721 $667,000
Q4 2020

Feb 12, 2021

SELL
$122.97 - $147.0 $9,222 - $11,025
-75 Reduced 1.61%
4,587 $596,000
Q3 2020

Nov 13, 2020

BUY
$121.19 - $165.49 $47,627 - $65,037
393 Added 9.21%
4,662 $679,000
Q2 2020

Aug 05, 2020

SELL
$104.21 - $156.44 $76,385 - $114,670
-733 Reduced 14.65%
4,269 $632,000
Q1 2020

May 14, 2020

SELL
$93.12 - $133.99 $39,296 - $56,543
-422 Reduced 7.78%
5,002 $544,000
Q4 2019

Feb 13, 2020

SELL
$74.51 - $124.23 $332,612 - $554,562
-4,464 Reduced 45.15%
5,424 $625,000
Q3 2019

Nov 12, 2019

SELL
$70.9 - $87.82 $118,473 - $146,747
-1,671 Reduced 14.46%
9,888 $795,000
Q2 2019

Aug 13, 2019

BUY
$65.86 - $92.79 $85,420 - $120,348
1,297 Added 12.64%
11,559 $839,000
Q1 2019

May 14, 2019

BUY
$72.76 - $93.45 $174,551 - $224,186
2,399 Added 30.51%
10,262 $959,000
Q4 2018

Feb 05, 2019

BUY
$62.67 - $88.33 $215,334 - $303,501
3,436 Added 77.61%
7,863 $573,000
Q3 2018

Nov 14, 2018

SELL
$87.52 - $122.67 $276,038 - $386,901
-3,154 Reduced 41.6%
4,427 $387,000
Q2 2018

Aug 10, 2018

BUY
$88.31 - $107.8 $135,025 - $164,826
1,529 Added 25.26%
7,581 $747,000
Q1 2018

May 14, 2018

BUY
$115.92 - $148.54 $379,869 - $486,765
3,277 Added 118.09%
6,052 $721,000
Q4 2017

Feb 14, 2018

SELL
$114.49 - $139.98 $187,305 - $229,007
-1,636 Reduced 37.09%
2,775 $353,000
Q3 2017

Nov 14, 2017

BUY
$72.53 - $118.27 $29,302 - $47,781
404 Added 10.08%
4,411 $518,000
Q2 2017

Aug 14, 2017

BUY
N/A
4,007
4,007 $320,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.